Drugs / BEBT-908
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06164327 | Dec 2023 → Oct 2025 | relapsed/refractory diffuse large B-cell lymphoma | BeBetter Med Inc | Unknown | No outcome recorded |
| Phase 1 | NCT06082596 | Mar 2016 → Mar 2019 | non-Hodgkin lymphoma, refractory plasma cell neoplasm | BeBetter Med Inc | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07301138 | Dec 2025 → Dec 2028 expected | acute lymphoblastic leukemia | Ruijin Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06074107 | Jun 2020 → Dec 2023 | relapsed/refractory diffuse large B-cell lymphoma | BeBetter Med Inc | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BEBT-908 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07301138 ↗ |
| Action | Inhibit | “a HDAC/PI3Kα inhibitor” NCT07301138 ↗ |
| Route | Intravenous | “intravenous drip” NCT06074107 ↗ |